Table 3 Median costs and benefits of the baseline response against malaria compared to counterfactuals, 2020–2030
Scenario comparisons (Baseline—Intervention) | Clinical cases averted | Reported cases averted | Deaths averted | Economic benefits (NPV USD) | Cost (USD) (discounted) |
|---|---|---|---|---|---|
Fully funded NSP scenario vs baseline | 37,434,462 | 21,221,433 | 2683 | 14.1 billion | 1.31 billion |
Elimination scenario (HSA) vs baseline | 85,571,086 | 51,251,099 | 4468 | 31.7 billion | 961.3 million |
| Â | Additional clinical cases | Additional reported cases | Additional deaths | Additional economic losses (NPV USD) | Â |
|---|---|---|---|---|---|
Baseline vs reverse I | 38,220,597 | 24,411,310 | 2497 | 14.1 billion | Â |
Baseline vs reverse II | 12,974,304 | 8,914,008 | 1350 | 4.4 billion | Â |